We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR... Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. Show more
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Companyβs in vivo gene...
U.S. index futures show slightly negative fluctuations on a day with a limited economic agenda, as investors await statements from key Federal Reserve officials. Throughout the day, figures such...
Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease On track to present...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast...
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with...
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.63 | 11.6666666667 | 5.4 | 6.69 | 4.91 | 2444882 | 5.38166256 | CS |
4 | 0.14 | 2.37691001698 | 5.89 | 6.69 | 4.91 | 1895264 | 5.45572402 | CS |
12 | -1.92 | -24.1509433962 | 7.95 | 11.58 | 4.91 | 2007443 | 7.37929036 | CS |
26 | -2.48 | -29.1421856639 | 8.51 | 11.69 | 4.91 | 1901611 | 8.40910666 | CS |
52 | -3.52 | -36.8586387435 | 9.55 | 11.91 | 4.91 | 1829388 | 8.45254546 | CS |
156 | -27.48 | -82.0053715309 | 33.51 | 73.025 | 4.91 | 1768402 | 17.8147168 | CS |
260 | -16.44 | -73.1642189586 | 22.47 | 99.95 | 4.91 | 1541360 | 25.32009129 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions